Genetic Engineering & Biotechnology News breaks a Cellzome/GlaxoSmithKline embargo
Fierce Biotech picked up the item, reporting that Cellzome had “inked a second drug discovery pact with GlaxoSmithKline in the field of inflammatory disease. Under the terms of the agreement, Cellzome will receive about $44.79 million in upfront payments.” (Read more about the first deal from 2008 here.)
The news was embargoed until a minute after midnight GMT Wednesday, which is 7:01 p.m. Eastern Tuesday (today). Cellzome sent out a press release at about 4 p.m. GMT Monday, according to the InVivo Blog‘s Chris Morrison, who tipped me off to the break.
Genetic Engineering & Biotechnology News posted their piece — which was called a “press release” here — sometime before 2:30 Eastern, and took it down as soon as they realized the mistake, a staffer there tells me.
Cellzome did not threaten any sanctions against the publication, and the discussion was “amicable,” the staffer said.
Morrison called this “a drum-up-the-coverage PR embargo.” By email, he told me:
It’s an interesting enough deal that we’d probably have covered it w/o the “embargo”. I guess they figured give the CEO time to talk to everyone so they get lots of coverage.
I have an email in to Cellzome, will update if I hear back.
This post was updated at 4:15 Eastern, after Genetic Engineering & Biotechnology News confirmed the break.